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Milling involves the application of mechanical energy to physically break down coarse
particles to finer ones and is regarded as a “topedown” approach in the production of fine
particles. Fine drug particulates are especially desired in formulations designed for
parenteral, respiratory and transdermal use. Most drugs after crystallization may have to
be comminuted and this physical transformation is required to various extents, often to
enhance processability or solubility especially for drugs with limited aqueous solubility.
The mechanisms by which milling enhances drug dissolution and solubility include al-
terations in the size, specific surface area and shape of the drug particles as well as milling-
induced amorphization and/or structural disordering of the drug crystal (mechanochem-
ical activation). Technology advancements in milling now enable the production of drug
micro- and nano-particles on a commercial scale with relative ease. This review will
provide a background on milling followed by the introduction of common milling tech-
niques employed for the micronization and nanonization of drugs. Salient information
contained in the cited examples are further extracted and summarized for ease of refer-
ence by researchers keen on employing these techniques for drug solubility and
bioavailability enhancement.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The process of drug dissolution is critical to the therapeutic
efficacy of a medicinal product regardless of its route of
administration. Dissolution involves the transfer of a solid
drug into solution in the surrounding physiological fluid. Thetical Processing Researc
543, Singapore. Tel.: þ65
Sia Heng).
g Pharmaceutical Univer
University. Production an
ns.org/licenses/by-nc-ndrate of dissolution of a drug is affected by factors embodied in
the NoyeseWhitney equation [1]. The extent to which drug
dissolution proceeds under prevailing physiological condi-
tions is governed by its aqueous solubility. Drug solubility is
defined as the amount of drug that passes into solution when
an equilibrium is established between the drug solute in so-
lution and any excess, un-dissolved drug to produce ah Laboratory, Department of Pharmacy, National University of
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ity and dissolution rate of a drug are often positively corre-
lated. The bioavailability of a drug is defined as the rate and
extent to which a dissolved drug is absorbed and becomes
available at its target site of action [3]. The bioavailability of a
drug is thus dependent not just on its dissolution and solu-
bility characteristics, but also on its membrane permeability
and associated absorption-related degradation.
Currently, the pharmaceutical industry faces considerable
challenges associated with the increasing number of poorly
water-soluble drugs coming through the drug discovery pipe-
line [4,5]. Despite promising pharmacological activity,many of
these drug candidates fall under class II of the Bio-
pharmaceutics Classification System (BCS), characterized by
high membrane permeability but low aqueous solubility [6].
These drugs exhibit erratic or incomplete absorption often
leading to unsatisfactory drug exposure in vivo and poor
bioavailability. Biopharmaceuticals and biotechnology-
derived therapeutic agents face similar challenges [7]. For
BCS class II drugs, the dissolution step is the rate-determining
factor in drug absorption. Pharmaceutical scientists are
constantly seeking new approaches to facilitate and enhance
the solubility and thus dissolution rate of BCS class II drugs.
Current strategies employed to improve the apparent solubi-
lity of a drug include the use of: (i) co-solvents (e.g. low mo-
lecular weight polyethylene glycols and propylene glycol) in
combination with water to dissolve the drug; (ii) complexing
agents (e.g. cyclodextrins and its derivatives) to form water-
soluble inclusion complexes of the drug [8] or (iii) hydrophilic
excipients (e.g. polyvinylpyrrolidones and high molecular
weight polyethylene glycols) as drug carriers for the prepara-
tion of solid dispersions in which the drug is dispersedTable 1 e Key advantages and disadvantages of common strat
bioavailability.
Technique Advantages
Use of co-solvents  Simple technique
 Lower costs involved
 Applicable for a wide range of drugs
Complexation using
cyclodextrins
 Improves the chemical stability of the drug
 May potentially enhance drug absorption by
cation of lipid barrier
Solid dispersions  Creates fine drug particles without excessive
tion of energy
 Fine particles are readily wetted with minim
agglomeration
 Wide range of hydrophilic polymers are avai
drug carriers
Chemical modification
(e.g. prodrugs)
 Prodrugs may enable drug targeting and imp
stability
Lipid formulations  Exploits the innate lipid digestion mechanis
body to enhance drug bioavailability
 Emulsifiable lipid formulations further enha
digestion and drug bioavailability
 Diversity of lipid excipients allow formulatio
flexibilities
 Lower risks of drug precipitation in-vivomolecularly or as ultrafine crystals [9]. Alternatively, the drug
molecule may be modified chemically by the syntheses of
suitable pro-drugs [10] or salt forms of the drug that often
exhibit greater aqueous solubility than the parent molecule.
However, drug precipitation is a common threat faced by some
of these formulations [11]. Precipitationmay arise from excess
drug coming out of solutionwhen a previously supersaturated
drug solution is diluted upon administration. For oral formu-
lations, drug precipitationmaybe triggered by the changing pH
environment of the gastro-intestinal tract. To ensure that a
drug stays in solution up till the point of absorption, lipids and
oils have been employed as drug carriers. Lipid formulations of
drugs basically comprise drugs dispersed, but more often,
dissolved, in lipids or oils. These formulations improve drug
bioavailability by exploiting the innate lipid digestion and
absorption mechanisms in the body. Depending on the
chemical nature of the lipid, the formulation may also self-
emulsify in the gastro-intestinal tract to facilitate lipid diges-
tion and maximize drug absorption. The advantage of lipid
formulations is that the drug is maintained in a solubilized
state prior to absorption. A comprehensive reference on oral
lipid-based formulations can be found in the book edited by
David J. Hauss [12]. The key advantages and disadvantages of
the different strategies employed to improved drug dissolu-
tion and bioavailability are highlighted in Table 1.2. Milling
Apart from the techniques aforementioned, another strategy
employed to improve solubility and ultimately, bioavailability
of poorly water-soluble drugs is milling. The terms milling,egies employed to improve drug dissolution and
Disadvantages
 Toxicity of solvents
 Risk of drug precipitation in-vivo
 Limited to liquid formulations
modifi-
 Successful complexation depends on both chemical
and geometrical properties of drug molecule
 Large amounts of cyclodextrins may be required due
to low complexation efficiencies
 Higher costs involved
applica-
al risk of
lable as
 Preparation method is difficult to scale up
 Amorphous drug forms created are physically unsta-
ble and may convert to crystalline forms during stor-
age, accelerated by moisture absorption by the
hydrophilic carrier
rove drug  Toxicity potential of prodrugs
 Fate of prodrugs is difficult to predict in-vivo due to
biological variations in theway they are handled in the
body
ms of the
nce lipid
n
 Amount of lipids typically present in the formulation
may be insufficient to trigger an appropriate physio-
logical response to enhance drug bioavailability
 Quality control of lipid-based formulations is
challenging due to the complex and diverse
physicochemical properties of lipids and the lack of
standardized testing methods
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often used interchangeably. Milling is a unit operation where
mechanical energy is applied to physically break down coarse
particles to finer ones and hence, is regarded as a “topedown”
approach in the production of fine particles [13]. As virtually
every drug can be comminuted to fine particles regardless of
its solubility in aqueous or non-aqueous solvents, the “tope-
down” approach has wider commercial and industrial appli-
cations than the “bottom-up” approach (e.g. precipitation)
where fine particles are constructed from their dissolved
molecular state and suitable solvents/anti-solvents of the
drug need to be selected.
Traditionally, milling is carried out to facilitate the extrac-
tion of crude drugs or to improve their bulk processing prop-
erties. Cutter mills, roller mills, pestle and mortars and runner
mills may be employed for this purpose. In these milling op-
erations, the dried crude drug may be cut by sharp blades
(cutter mill), impacted by hammers or crushed/compressed by
the application of pressure (roller mill, pestle and mortar). As a
limited amount of energy is imparted, the milled particles
remain relatively coarse. Technological advancements in
milling equipment now enable the production of ultrafine drug
particles down to the micron or even sub-micron dimensions.
Griseofulvin, an anti-fungal drug, represents one of the pio-
neering examples of drugs where solubility and absorption
were enhanced bymilling.Milling of carbamazepinewas found
to be more effective in enhancing drug dissolution than
formulating the drug as a solid dispersion due to polymorphic
transformation of the drug (from the b to a form) in the solid
dispersion system [14]. Other early examples of drugs where
milling has resulted in enhanced dissolution include nitro-
furantoin, nifedipine, ibuprofen and spironolactone [3].
Milled drug particles are rarely used as it is and are in-
termediates in the production of pharmaceutical dosage
forms. Oftentimes, they are cohesive and exhibit poor flow
properties, largely due to their higher surface energies
compared to their coarser counterparts. To alleviate this
problem, inert pharmaceutical excipients or fillers, e.g. cal-
cium phosphate, lactose, mannitol and other sugars etc., are
often added and mixed with the milled drug particles to
improve powder flow. Alternatively, the drug particles may be
granulated with these fillers to form granules which typically
exhibit improved flow properties and content uniformities
than the corresponding physical mixtures. Apart from
improving flow during manufacturing, these fillers may also
serve other functions e.g. modifying drug release, enhancing
drug stability and dissolution as well as taste-masking.3. Mechanisms by which milling improves
drug dissolution and solubility
Milled products possess specific physical attributes that
contribute to improved drug dissolution and solubility. Milling
reduces the size and alters the size distribution of the drug
particles. Thesepropertiesmaybemeasuredby light scattering
techniques such as photon correlation spectroscopy (5 mm
down to 0.001 mm) and laser diffraction (0.05 mme2000 mm),
respectively [15]. By virtue of their smaller size,milled particles
possess larger specific surface area compared to their unmilledcounterparts. Based on the NoyeseWhitney equation, this is
likely to increase the dissolution rate of the milled drug parti-
cles if the particles can also be adequately wetted. Milled par-
ticles possess higher surface free energies and this, coupled
with their thinner diffusion boundary layers [16] further
enhance the dissolution rate of the milled drug substance.
Apart from size, milling also alters the surface roughness
and shape of particles. This has been demonstrated in many
studies on the development of inhalable dry powder formu-
lations. It has been shown that the surface properties ofmilled
particles can affect wetting [17] and dissolution behavior [18].
Furthermore, milled particles are rarely isometric or spherical
in shape. Compared to particle size, considerably lesser
attention has been devoted to the impact of particle shape
[19e23] on drug dissolution, solubility and bioavailability
although early studies have demonstrated that when particles
are platelet-like or possess needle shapes, the shape factors of
particles are closely related to their dissolution rates and
profiles [24e28]. Particle shape may be determined by image
analysis techniques, laser diffraction [29], scanning electron
microscopy, transmission electron microscopy and atomic
force microscopy.
In a milling operation, particle size reduction ceases at a
practical limit [30] beyond which the material becomes pro-
gressively difficult to comminute even when milling time is
prolonged. When particle size reduction has reached a critical
threshold, the continued transfer of mechanical energy from
the mill to the drug substance leads to the accumulation of
defects on the drug crystal and disordering of the crystal
structure, eventually bringing about the disappearance of the
order in the positions of atoms or molecules in the crystal [31].
These defects may manifest throughout the entire crystal
resulting in complete amorphization of the drug or be
restricted to the crystal surfaces in which case a thin, amor-
phous (disordered) layer may be formed around a crystalline
(ordered) core [32,33]. Under these circumstances, the drug is
said to be “mechanochemically-transformed” or “activated” by
the milling process. Drug amorphization as a result of milling
improves the aqueous solubility and dissolution characteristics
of the drug. It may also confer additional benefits such as
improved compressibility [34]. Milling-induced amorphization
of drug substances have been reported for piroxicam [35],
budesonide [36], naproxen [37] and indomethacin [38] amongst
many others. However, the disadvantage of these solid state
transformations is that amorphous regions or crystal defects
created may be thermodynamically unstable, leading to
amorphous-crystalline inter-conversions of the drug during
storage, alteration of particle size distribution, specific surface
area, chemical and physical reactivity, dissolution or overall
performance of the drug product [39].
An approximate measure of the extent of milling-induced
drug activation may be obtained experimentally by deter-
mining the amorphous content or residual crystallinity before
and after milling the drug substance using standard solid-
state characterization tools such as x-ray powder diffraction
(XRPD), Raman spectroscopy or differential scanning calo-
rimetry. As the information obtained from these different
techniques complement each other, a combination of tech-
niques is often desired to fully elucidate the solid-state con-
dition of the milled drug substance. The solubility of many
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methacin and phenylbutazone have been enhanced by
mechanochemical activation. Comprehensive information on
the mechanochemical activation of drugs can be obtained in
the review by Boldyrev [31].4. Milling adjuvants
The micro or nanoparticles produced from milling possess a
large surface/interfacial area, increased free energy and
decreased thermodynamic stability. These factors promote
particle agglomeration. Mechanochemically-activated parti-
cle surfaces and amorphous regions generated during milling
also increase the surface free energy of the particles, favoring
agglomeration. In practice, it has been suggested that particle
agglomeration arising from van der Waals' and other forces
(e.g. electrostatic forces) become significant at particles sizes
of about 30 mm and below [41]. Fine, hydrophobic drug parti-
cles less than 5 mm in size are known to be exceptionally prone
to agglomeration and this is attributed to the inter-particulate
cohesive forces between them. Hence, when milling is pro-
longed, particle agglomeration may supersede particle frac-
ture and this severely reduces the efficiency of the mill over
time. Agglomeration occurring during or after milling reduces
the effective surface area of the drug particles, with their
resultant dissolution rate and bioavailability, being compara-
ble or even less than their untreated counterparts. It was
observed that continued milling of ketoconazole in a cryo-
genic impact mill led to apparent particle size growth by fine
particle mechanofusion [42]. Aspirin, phenacetin and pheno-
barbital are known to be prone to the effects of aggregation
during particle size reduction.
In most cases, drugs are co-milled together with certain
adjuvants to minimize the conditions promoting agglomera-
tion. These adjuvants are inert, non-toxic pharmaceutical
excipients that function as a carrier and/or stabilizer of the
drug in the milled product. There is considerable variation in
the amount of excipient employed, with drug to excipient
ratios ranging from 1:3 to 50:1 w/w being reported in the
literature [43]. Typically, the excipient employed is hydro-
philic in nature and notable examples are hydrophilic poly-
mers such as polyvinylpyrrolidone, cellulose ethers,
polyethylene glycol, polyvinyl alcohol or poloxamers; surfac-
tants, ionic or non-ionic; inorganic materials like magnesium
aluminometasilicate [44] and cyclodextrins. By conferring
hydrophilicity to the hydrophobic drug particle surfaces, the
added excipient also enhances the wettability, solubility and
bioavailability of the poorly water-soluble drug.
The efficiency of a particular stabilizer depends on its po-
tential for interaction with the drug compound. Generally,
milling may be conducted with the drug in its dry state (dry
milling) or suspended in a liquid medium (wet milling). In dry
milling, themechanical energy imparted fosters drug-excipient
interactions via van derWaals forces or hydrogen bonding. The
resultant drug-excipient composite particles are often stable,
exhibit low tendencies to agglomerate and retain the activated
status of the drug [31,34]. In wet milling, the addition of sur-
factants (e.g. sodium lauryl sulfate and polysorbate 80) and
polymers (e.g. hydroxypropylmethyl cellulose, hydroxypropylcellulose, polyvinylpyrrolidone and poloxamer), singly or in
combination, helps to minimize the agglomeration of sus-
pendedparticles via electrostatic and stericmechanisms. Steric
stabilization is achieved when long chain polymers are adsor-
bed onto the surfaces of the drug particles, forming a physical
barrier that prevents the close approach of the particles. The
chain length, molecular weight [45], hydrophobicity [46,47],
concentration, shape and surface energy [48] of the polymer
will influence the efficiency of adsorption. The method of
adding thepolymer (periodic additionsoradditionat the start of
milling process) also affected its stabilizing properties [49].
Electrostatic stabilization is achieved when charged polymers
or ionic surfactants become Adsorbed on the surfaces of the
drug particles and lower their apparent charge. Apart from
preventingagglomeration, thesestabilizingmoleculesmayalso
aid in preventing crystal growth (Ostwald ripening) that could
adversely alter the dissolution and bioavailability of the drug
suspension after storage. Hydroxypropylmethyl cellulose (3
cps) was found to stabilize and minimize crystal growth in a
nanosuspension of an unidentified drug compound NSV-102
(Novartis Pharma) produced by media milling, an example of
wet milling. This was attributed to improved surface coverage
owing to its stronger interaction with the drug in comparison
with other stabilizers, pluronic F-68, pluronic F-127, sodium
lauryl sulfate and polyvinylpyrrolidone K-30, investigated [50].
A screening study of polymers, copolymers, and surfactants
has revealed that the stabilizing performance of surfactants to
be the best followed by linear synthetic polymers and semi-
synthetic polymers for the 9 drug compounds (cinnarizine,
griseofulvin, indomethacin, mebendazole, naproxen, phenyl-
butazone, phenytoin, itraconazole and loviride) investigated
[51]. Commonadjuvants employed in the dry andwetmilling of
drugs are summarized in Tables 2e4.
Achieving the desired size, shape and activation of drug
particles in a milling process often requires extensive opti-
mization of a multitude of process and material-related vari-
ables. In terms of processing, a prudent selection of the type of
milling equipment is required, followed by the adjustment of
the conditions of milling such as the duration of milling,
material feed rate and other operational or equipment pa-
rameters. Occasionally, a combination of milling techniques
may be necessary to achieve the desired outcomes. When
such combination techniques are used, numerous process-
related variables need to be adjusted and fine-tuned as this
allows the unique advantages of each milling technique to be
synergistically combined for the desired outcome. Suitable
and compatible adjuvants have to be selected to minimize
agglomeration, improve wetting, stability and resultant solu-
bility of the milled drug particles. The following sections will
provide the background from literature on the common mill-
ing techniques employed for size reduction.5. Milling techniques for the production of
microparticles
5.1. Fluid energy milling
Fluid energy milling, sometimes referred to as air jet milling,
effectively reduces the size of drug particles from the range of
Table 2 e Summary of examples obtained from scientific literature on the use of media milling for the production of drug
nanoparticles.
Drug Adjuvants Variables Mean particle size
or particle size
range attained
Equipment Authors
Naproxen Vit E TPGS,
pluronic F127,
SLS, DOSS, HPMC
3 cps
Different
stabilizers
<500 nm Planetary mill (Retsch PM 400 MA,
Retsch, Haan, Germany)
[122]
Griseofulvin HPC, SLS Concentration of
HPC
50-250 nm Wet-stirred media mill (Microcer,
Netzsch Fine Particle Technology,
PA, US)
[123]
Unidentified compound
NVS-102
Vit E TPGS Concentration of
Vitamin E TPGS
<300 nm Planetary mill (PM400, Retsch,
Newtown, PA, US)
[124]
Fenofibrate HPMC, DOSS Milling speed <700 nm Agitator ball mill (Dyno Mill
Research Lab, WAB, Muttenz,
Switzerland)
[125]
Ibuprofen (transdermal) Pluronic F127, Vit
E TPGS, PEG, PVP
Different
stabilizers
123 ± 4 nm Planetary mill (PM400, Retsch,
Haan, Germany)
[83]
Paclitaxel
(intraperitoneal)
Pluronic F68 and
F127
Different
stabilizers and
stabilizer ratios
307 ± 12 nm Roller-mill (Peira, Beerse, Belgium) [126]
Compound A (oral) Vit E TPGS, HPMC
3cps
Stabilizer level
and drug loading
138.6 nm Media mill (Netzsch Labstar Mill,
Exton, PA, USA) with a zeta agitator
in the recirculation mode
[127]
Griseofulvin, naproxen,
fenofibrate (oral)
HPMC (E15LV),
SLS
Effect of different
drugs on film
properties
163 nm
(griseofulvin);
201 nm (fenofibrate);
144 nm (naproxen)
Wet-stirred media mill (Microcer,
Netzsch Fine Particle Technology,
LLC, PA, US)
[73]
Indomethacin
(inhalation)
Poloxamer 188 e 485 nm Planetary ball mill (Pulverisette 7
Premium, Fritsch, Germany)
[86]
Phenytoin (oral) PVP, SLS e ~300 nm Oscillating beads-milling
apparatus (Multi-Beads Shocker,
Yasui Kikai, Osaka, Japan)
[84]
Itraconazole,
fenofibrate,
griseofulvin,
ibuprofen,
azodicarbonamide,
sulfamethoxazole
HPMC (4000
e5600 cp), Tw80,
SLS, sodium
alginate
Different drugs
and stabilizers
8.72 ± 5.66 mm
(itraconazole);
3.37 ± 2.48 mm
(fenofibrate);
2.65 ± 1.12 mm
(griseofulvin)
3.30 ± 2.18 mm
(ibuprofen)
0.67 ± 0.52 mm
(azodicarbonamide)
0.63 ± 0.56 mm
(sulfamethoxazole)
Wet milling machine (Micros-
0 Ring Mill, Nara Machinery, Tokyo,
Japan)
[49]
Unidentified compound
NVS 102 (oral)
Vit E TPGS,
pluronic F68 and
F127, HPMC 3cps,
SLS, PVP K-30
Effect of different
stabilizing agents
on crystal growth
230.2 ± 0.257 nm Media mill (Netzsch Labstar Mill,
Exton, PA, US) with a zeta agitator
in the recirculation mode
[50]
Phenytoin, nifedipine,
pranlukast (oral)
PVP, HPC, HPMC,
PVA, SLS, Tw80
Different scales
of preparation
292 nm (phenytoin)
353 nm (nifedipine)
334 nm (pranlukast)
Oscillating beads-milling
apparatus (Multi-Beads Shocker,
Yasui Kikai, Osaka, Japan)
[128]
Miconazole
(ophthalmic)
SLS, sodium
docusate,
benzalkonium
chloride, HPC-LF,
HPC-EF, PVP,
poloxamer,
HPMC
Formulation
variables
140 ± 1 nm Media mill (Netzsch Labstar Mill
Selb, Germany)
[129]
Candesartan cilexetil
(oral)
SLS, poloxamer
188, PVP K-30,
HPMC 6 cps
Drug and
stabilizer
concentrations
127 nm Heidolph mixer (RZR2051Control,
Rose Scientific, Alberta, Canada)
[85]
(continued on next page)
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Table 2 e (continued )
Drug Adjuvants Variables Mean particle size
or particle size
range attained
Equipment Authors
Cilostazol (oral) HPC, DOSS Different milling
processes
260 nm Agitator ball mill (Dyno-Mill KDL
Type-A, Willy A. Bachofen AG
Maschinenfabrik, Basel,
Switzerland)
[130]
Zn-insulin
(subcutaneous and
intraduodenal)
Sodium
deoxycholate,
pluronic F68
Different
stabilizers
<150 nm Low energy wet media mill
(Stoneware, East Palestine, OH, US)
[131]
Ethyl diatrizoate (radio-
contrast medium)
Poloxamine 908 Different
formulation
variables
230 ± 10 nm Roller mill (Stoneware, East
Palestine, OH, US)
[132]
Abbreviations: DOSS, dioctyl sulfosuccinate sodium; HPC, hydroxypropylcellulose; HPMC, hydroxypropylmethyl cellulose; PEG, polyethylene
glycol; PVA, polyvinyl alcohol; PVP, polyvinylpyrrolidone; SLS, sodium lauryl sulfate; TPGS, d-alpha tocopheryl polyethylene glycol 1000 suc-
cinate; Tw80, Tween 80 (polysorbate 80); Vit, vitamin.
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high velocity compressed air streams are injected into a
chamber where the starting raw materials are fed by a rate-
controlled feeder (Fig. 1). As the particles enter the air
stream, they are accelerated and caused to collide with each
other and the wall of themilling chamber with high velocities.
Particle size reduction is brought about by a combination of
impact and attrition. Impacts arise from collisions between
the rapidly moving particles and particles onto the wall of the
milling chamber. Attrition occurs at surfaces of particles as
theymove rapidly against each other, resulting in shear forces
that may break them up. A classifier may be integrated into
the milling system such that only particles that are suffi-
ciently fine or have acquired dimensions below the pre-
defined cut-off size are entrained in the exhausting air
stream and removed from the milling chamber. Classification
may be effected by a spinning wheel classifier where the
centrifugal force generated by the high spinning speed of the
fluted wheel limits the cut-off size of particles that can
accompany the exhausting air through the wheel to the air
exhaust outlet. Alternatively, a large tubular shaped milling
chamber, circular or oblong, may be used, with colliding air
jets at the periphery and the exhaust air leaving centrally,
causing a centrifugal classification system for the milled
particles. Longer durations of milling are required when finer
particles are desired. This process is suitable for meltable
materials [52] and drugs that are heat-sensitive. It is also
capable of manufacturing large quantities of powder
continuously.
Fluid energy milling has been successfully employed for
themicronization of many drugs for the purpose of improving
their dissolution and solubility characteristics. Some exam-
ples include ibuprofen [53], salbutamol sulfate [54] and feno-
terol hydrobromide [55]. Drugs are commonly milled on their
own although occasionally, co-milling with suitable excipi-
ents is carried out. It was reported that fluid energy milling of
a blend of fenofibrate, a poorly water-soluble drug, together
with a mixture of hydrophilic excipients resulted in faster
drug dissolution rates from a rapidly disintegrating dosage
form compared to a powder formulation of identical compo-
sition prepared by mixing pre-milled fenofibrate with theexcipient mixture [56]. This was attributed to the persistence
of aggregates of pure, jet-milled fenofibrate which retarded
drug dissolution. In an attempt to improve the bioavailability
of EMD 57033, a poorly water-soluble calcium sensitizing
agent, Vogt et al. [57] found that co-grinding a mixture of EMD
57033with lactose and hydroxypropylmethyl cellulose using a
fluid energymill wasmore effective thanmicronizing the drug
alone or spray drying a nanosuspension of the drug. Fluid
energy milling of ibuprofen together with nanosilica was
carried out by Han and co-workers [58]. It was found that fluid
energy milling not only decreased the size of drug particles
from 102 to <10 mm but also facilitated the coating of nano-
silica on the surfaces of the milled drug particles. This surface
modification brought about by milling reduced particle
agglomeration and improved powder flow.
However, the popularity of fluid energy milling has some-
what dipped following the development of other milling tech-
niques capable of effecting greater extents of size reduction,
enabling the production of sub-micron or nanoparticles at
commercial scale. The lowest mean particle diameters
achievable by fluid energy milling is 3e5 mm with size distri-
bution ranging froma few hundred nanometers to about 25 mm
and a very low fractional content of nanoparticles [59]. None-
theless, this milling technique remains as a benchmark for the
evaluation and development of new milling methods and
strategies. In the context of drug solubility enhancement, fluid
energy milling may be employed in combination with other
particle design techniques (e.g. “bottom-up” approaches such
as precipitation, crystallization) to produce drugmicroparticles
with desirable morphological characteristics. Fluid energy
milling of ibuprofenwas investigated and found generally hard
to mill in its dry state due to its ductility and lowmelting point
[53]. In the study, ibuprofen crystals of different sizes (<40mmor
50e250 mm) and morphologies (plate-like and needle-like crys-
tals) were first produced by controlled crystallization. It was
reported that the drug could be milled down to less than 5 mm,
which is below the reported particle size for brittleeductile
transition of the drug. Furthermore, it was observed that the
sizeandmorphologyof the startingdrugcrystals influenced the
milling outcome. Compared to plate-like crystals, needle-like
crystals were more susceptible to micronization. Milled
Table 3 e Summary of examples obtained from scientific literature on the use of high pressure homogenization for the
production of drug nanoparticles.
Drug Adjuvants Operating
parameters
Minimum/avg
particle size
Equipment Ref
Telmisartan (oral) b-cyclodextrin,
meglumine
15 cycles at 1200 bar 698 ± 23 nm High pressure homogenizer (Niro
Soavi, Italy)
[133]
Nitrendipine (oral) PVA 20 cycles at 1000 bar 175 nm High pressure homogenizer
(AH100D, ATS Engineering,
Shanghai, China)
[99]
Ketoprofen PLGA, CO2, PVA, ethyl
acetate
Pressure drop of
900 bar & up to 150
passes
1.34 mm High pressure piston pump
(Haskel, Burbank, CA, US)
[97]
Quercetin (topical) Tristearin,
hydrogenated
phosphatidylcholine
1 or 2 cycles at 1000 bar 486 nm Hot and cold high pressure
homogenizer (Panda 2K GEA; Niro
Soavi, Parma, Italy)
[134]
Unidentified compound
PIK75 (intravenous)
Pluronic F68, lipoid S75 15 cycles at 7250 psi, 5
cycles at 15 000 psi and
15 cycles at 18,000 psi
at 2e4 C.
187.6 ± 19.11 nm High pressure homogenizer
(Emulsiflex-C3, Avestin, Canada)
[135]
Curcumin PVA, PVP, Vit E TPGS,
SLS, Na CMC
2 cycles each at 300,
500 & 1000 bar
followed by 20 cycles
at 1500 bar
500-700 nm High pressure homogenizer
(Micron LAB 40, APV Deutschland,
Unna, Germany)
[136]
Fish oil (intravenous) Lecithin and glycerol 5 cycles at 500
e1500 bar
150 nm High pressure homogenizer
(Micron LAB 40, APV Deutschland,
Unna, Germany)
[137]
Tanshinone IIA
(intravenous)
Soybean lecithin,
poloxamer 188,
glycerol, soybean oil,
medium-chain
triglyceride
3 cycles at 100 MPa 251.7 ± 16.6 nm High pressure homogenizer
(Avestin, Ottawa, Canada)
[138]
Itraconazole (oral) Chitosan, N-trimethyl
chitosan,
polyethyleneimine
2 cycles each at 150,
500, 1000 bar followed
by 15 cycles, 1350 bar
267.6 ± 15.8 nm High pressure homogenizer
(AH100D, ATS Engineering,
Shanghai, China)
[139]
Emodin (oral) Poloxamer 188, Tw80,
compritol 888 ATO,
GMS, stearic acid,
lauric acid
500, 700, 900 bar with
3, 4 and 5 cycles
28.6 ± 3.1 nm High pressure homogenizer
(NS1001L, Niro Soavi, Italy)
[140]
Beclomethasone
dipropionate
(inhalation)
e 2 cycles each at 150 &
300 bar followed by
500 bar for different
homogenization
cycles
247 nm High pressure homogenizer
(AH110D, ATS Engineering, Italy)
[141]
Baicalein (oral and
parenteral)
Tw80, SLS, poloxamer
188
5 cycles at 200 bar
followed by 5e35
cycles at 1000 bar
287 ± 5 nm High pressure homogenizer (NS
1001L, Niro Soavi, Italy)
[142]
Recombinant human
epidermal growth
factor (topical)
Hydrogenated
phospholipid,
triglycerides,
diethylamine
cetylphosphate,
butylated hydroxyl
toluene in ethanol, Na
ascorbyl phosphate,
EDTA
2 cycles at 1000 bar 155.57 ± 2.59 nm High pressure homogenizer
(Emulsiflex-C3, Avestin, Canada)
[143]
Atorvastatin (oral) Chitosan 1e3 cycles at 20,000
e40,000 psi
214.8 ± 15.8 nm High pressure homogenizer (Nano
DeBEE, BEE International, MA, US)
[144]
Pranlukast (oral) Poloxamer 407, PEG
200
680 bar e 15 circles,
1048 bar e next 9
circles & 1500 bar e
last 9 circles
315.4 ± 4.2 nm High speed homogenizer (Ultra-
Turrax T-18 Basic, IKA-Werk,
Staufen, Germany)
[145]
Quercetin Tw80 2 cycles each at 300 &
500 bar, 1 cycle at
1000 bar followed by 20
cycles at 1500 bar
338.3 nm High pressure homogenizer
(Micron LAB 40, APV Deutschland,
Unna, Germany)
[146]
(continued on next page)
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Table 3 e (continued )
Drug Adjuvants Operating
parameters
Minimum/avg
particle size
Equipment Ref
Fenofibrate (oral) Soybean protein
isolate, whey protein
isolate, egg
phosphatidylcholine,
b-lactoglobulin,
cremophor EL and RH
40, poloxamer 188,
solutol HS15, Tw80
1 to 10 cycles at100 to
800 bar
200 to 250 nm High pressure homogenizer (ATS
Engineering, Ontario, Canada)
[147]
Astaxanthin (topical) Tween 60, glyceryl
citrate/lactate/
linoleate/oleate, liquid
paraffin, ceramide, co-
anti oxidants,
cholesterol
1000 bar 160e190 nm High pressure homogenizer
(Panda, Niro Soavi, Italy)
[148]
Flurbiprofen (ocular) Glycerol behenate,
saturated fatty acid of
C18, Tw80
3 homogenization
cycles at 600 & 60 bar
in first & second stage,
respectively, at 85 C
<199 nm High pressure homogenizer (APV-
2000, Invensys, Albertslund,
Denmark)
[149]
Puerarin Lecithin and HPMC 6 cycles at 800 bar
followed by 15 cycles
at 1500 bar
448.9 ± 15.1 nm High pressure homogenizer
(Emulsiflex-C3 Avestin Inc.,
Ottawa, Canada)
[150]
Camptothecin e 2 cycles each at 200 &
400 bar followed by 20
cycles at 1300 bar
125.1 ± 8.6 nm High pressure homogenizer
(NS1001L-Panda 2K, Niro Soavi,
Italy)
[151]
Co-enzyme Q10 (oral) Sucrose monolaurate,
mixture of mono, di &
triglycerides, medium-
chain triglycerides
20 homogenization
cycles at 800 bar
282 ± 15 nm
(nanocrystals);
143 ± 10 nm
(lipid nanoparticles)
Melt high pressure homogenizer
(ATS Engineer, China)
[152]
Quercetin Tw80 2 cycles each at 300 &
500 bar, 1 cycle at
1000 bar & finally, 20
cycles at 1500 bar
338 nm High pressure homogenizer
(Micron LAB 40, APV Deutschland,
Unna, Germany)
[153]
Lutein (oral and dermal) Decyl glycoside 2 cycles each at 200,
500 & 1000 bar
followed by 25 cycles
at 1500 bar
429 nm High pressure homogenizer
(Micron LAB 40, APV Deutschland,
Unna, Germany)
[154]
Alkylpolyglycoside C8-
10 (dermal)
Neutral oil, glycerol
distearate,
3 cycles at 750 bar 150.40 ± 3.79 nm High pressure homogenizer
(EmulsiFlex-C3, Avestin, Germany)
[155]
Piroxicam (oral) Poloxamer 188 3 cycles at 500 bar and
30 cycles at 1500 bar
414.3 ± 21.1 nm High pressure homogenizer
(EmulsiFlex-C5 Avestin, Ottawa,
Canada)
[156]
Glibenclamide (oral) e 2 cycles at 500 bar
followed by 20 cycles
at 1500 bar
335 nm High pressure homogenizer
(Micron LAB 40, APV Deutschland,
Unna, Germany)
[101]
Itraconazole (inhalation) Sodium taurocholate,
polyethylene 1000
succinate, poloxamer
407, Vit E
300 cycles at 20 000 psi 221 ± 10 nm High pressure homogenizer
(Emulsiflex-C5 Avestin, Ottawa,
Canada)
[157]
Abbreviations: CMC, carboxymethyl cellumose; EDTA, ethylenediamine tetraacetic acid; GMS, glycerol monostearate; HPMC, hydrox-
ypropylmethyl cellulose; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic acid); PVA, polyvinyl alcohol; PVP, polyvinylpyrrolidone; Vit,
vitamin; SLS, sodium lauryl sulfate; Tw80, Tween 80 (polysorbate 80).
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exhibited smaller volume mean diameters compared to their
coarser counterparts for both morphologies of ibuprofen par-
ticles. The authors explained that with proper control of the
crystal attributes of the starting material, fluid energy milling
might be equally, if not more effective than wet milling in
reducing the particle size of drugs. Despite it being a micron-
ization technique, fluid energy milling also plays a significant
role in the development of nanoparticulate drug deliverysystems. Drug microparticles produced from fluid-energy
milling may be subjected to a subsequent milling process to
attain particles in nanoscale dimensions. In a study, horse-
radish peroxidase enzyme as a model drug was loaded in a
suitable polymer matrix and pre-micronized using a fluid en-
ergy mill [60]. The protein-polymer microparticles were then
subjected to a nanonization process (high pressure homogeni-
zation) to produce stable, protein-loaded nanoparticles with
controlled drug release properties.
Table 4 e Summary of examples obtained from scientific literature on the use of cryomilling for the production of drug
nanoparticles.
Drug Adjuvants Variables Observations Equipment Ref.
Phenytoin PVP e Novel ultra cryomilling
micronization technique using dry
ice beads and liquid nitrogen
Wet milling machine (RMB-
04, Aimex, Tokyo, Japan)
[102]
Phenytoin PVP, Eudragit L100,
HPMC, HPMC
acetate-succinate,
MCC, HPC, CMC
e Enhancement of dissolution rate
with phenytoin nanoparticles
Wet milling machine (RMB-
04, Aimex, Tokyo, Japan)
[105]
Indomethacin e Milling time Dissolution rate depended on the
milling time
Oscillatory ball mill (Mixer
Mill MM301, Retsch, Haan,
Germany)
[38]
Griseofulvin e Milling time Continued mode of attrition with
milling time
Cryogenic impact mill (Spex
CertiPrep 6750 Metuchen,
NJ, US)
[42]
Ketoconazole Continuedmilling caused apparent
particle growth
Furosemide PVP, inulin Milling time Solid state amorphization and
chemical decomposition
Cryogenic impact mill (Spex
CertiPrep 6750 Metuchen,
NJ, US)
[113]
g-Indomethacin e e Atomic pair-wise distribution
functions was better than x-ray
diffractograms in assessing the
degree of disorder
Oscillatory ball mill (Mixer
Mill MM301, Retsch, Haan,
Germany)
[158]
Indomethacin e e Correlation between physical
stability and relaxation time was
established for the same
amorphous systems prepared by
different methods
Oscillatory ball mill (Mixer
Mill MM301, Retsch, Haan,
Germany)
[110]
Phenytoin, ibuprofen,
salbutamol sulfate
e e No change in crystal form and
amorphization after milling
Wet milling machine (RMB-
04, Aimex, Tokyo, Japan)
[114]
Glibenclamide e e Transformation from crystalline to
amorphous state without chemical
decomposition
Cryogenic freezer/mill
(Spex SamplePrep 6770,
Metuchen, NJ, US)
[111]
Griseofulvin e Milling time Reduction of crystallinity due to
crystal defects rather than
amorphization of materials
Cryogenic impact mill (Spex
CertiPrep 6750 Metuchen,
NJ, US)
[115]
Ranitidine hydrochloride e Milling time Ranitidine hydrochloride
polymorphs form 1 and 2 could be
fully converted to the amorphous
form
Oscillatory ball mill (Mixer
Mill MM301, Retsch, Haan,
Germany)
[112]
Carbamazepine Saccharin e Higher amorphization with
cryogenic cogrinding than room
temperature cogrinding
Cryogenic impact mill (Spex
CertiPrep 6750 Metuchen,
NJ, US)
[106]
Whole inactivated
influenza virus
Chitosan, lactose,
trehalose
e Dry powder influenza vaccine
successfully formulated
Micro-ball mill (SPEX
CertiPrep 3117, Metuchen,
NJ, US)
[159]
Indomethacin polymorphs
and solvates
e e Amorphous materials obtained
after milling possessed similar Tg
but significant differences in their
physical stability
Cryogenic impact mill (Spex
CertiPrep 6750 Metuchen,
NJ, US)
[109]
Abbreviations: CMC, carboxymethyl cellulose; HPC, hydroxypropyl cellulose; HPMC, hydroxypropylmethyl cellulose; MCC, microcrystalline
cellulose; PVP, polyvinylpyrrolidone.
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Ballmilling isanotherpopular size reduction techniqueused for
the production of microparticles, especially in research labo-
ratories. Fundamentally, a ball mill comprises a vessel or vial
filledwith balls, or rods, constructed froma variety ofmaterials
such as ceramic, agate, silicon nitride, sintered corundum, zir-
conia, chrome steel, CreNi steel, tungsten carbide or plastic
polyamide (Fig. 2). Thematerial to bemilled is placed inside the
vessel,which ismade to rotate or vibrate at a particular speedorfrequency. The movement of the vessel causes the balls to
cascade or move in a particular pattern, colliding with each
other and with the opposing inner wall of the vessel. Size
reduction of the drug particles is effected from the impact they
receive from the balls aswell as attritive forces arising from the
movement of the balls relative to each other [61,62].
The quantities of the balls and starting material determine
the extent of fill of the vessel and the intensity of the milling
process. Typically, the vessel is filled by the balls and starting
material to 50% and 25% of the total volume of the vessel,
Fig. 1 e Schematic diagram of a fluid energy mill. Air is
introduced through specially-designed fluid inlets creating
sonic or supersonic air streams. Raw materials are
introduced into the violent and turbulent air stream. High
velocity collisions between the raw particles lead to
effective pulverization of the feed into smaller particles.
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case of a rotating vessel, rotation is usually carried out at
50e85% of the critical speed, defined as the speed atwhich the
balls cease to cascade owing to the centrifugal force imparted
by the rotating vessel. The critical speed may be estimated
based on the following relationship [63]:
Critical speed ðrpmÞ ¼ 54=
ﬃﬃﬃﬃﬃﬃ
Rft
p
where Rft is the diameter of the vessel measured in feet. As
the rotational speed of the vessel decreases, attrition plays aFig. 2 e Schematic diagram of a ball mill. The balls make up the
chamber.more dominant role in particle size reduction relative to
impaction and compression, yielding finer particles at the
expense of longer processing times. Apart from the speed of
rotation or vibration, the size, density and hardness of the
balls affect the rate and extent of particle size reduction.
Decreasing the size and/or increasing both the density and
hardness of the balls often increase the rate and extent of
particle size reduction.
The use of ball milling as a micronization technique for
enhancing drug solubility is well supported by literature
dating as far back as the 1970s. Apart from its comminution
function, ball milling also serves as an intensive mixing
technique capable of producing co-ground drug-excipient
mixtures comprising amorphous drug forms intimatelymixed
with suitable hydrophilic excipients at the molecular level.
This interaction between the drug and hydrophilic excipient
enhances the wetting and dissolution of the drug. Studies on
the vibrational ball milling of griseofulvin and phenytoin have
demonstrated that milling these drugs in combination with
microcrystalline cellulose resulted in amorphization of the
drug, enhancing its dissolution and bioavailability [64,65]. Ball
milling of ibuprofen and aluminum hydroxide was carried out
to facilitate complex formation between ibuprofen and
aluminum hydroxide as well as drug amorphization which
enhanced the dissolution of ibuprofen [66]. The incorporation
of excipients may, in some cases, mitigate milling-induced
drug amorphization. It was demonstrated that the co-milling
of salbutamol sulfate with crystalline excipients (a-lactose
monohydrate, adipic acid, magnesium stearate) in a ball mill
was effective in reducing milling-induced amorphization or
structural disorder of salbutamol sulfate [67]. Ball milling of
pure drug mixtures have also been investigated. More
recently, ball milling of a combination of two BCS Class II
drugs, simvastatin and glipizide, resulted in the formation of
stable co-amorphous mixtures [68].
Despite the efficiency of ball milling for size reduction or
amorphization, it is less amendable to scale up. By a flow-
through method, with vibrating balls or discs in the milling
chamber, milling efficiency can be improved. External jack-
eting for heat removal allows the mill to be used continuously
and will limit the rise in temperature within the milling
chamber.grinding media and drive rollers help to rotate the milling
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nanoparticles
6.1. Wet milling
Both fluid energy and ball milling techniques involve size
reduction of drug particles in their dry state. The extent of size
reduction achievable in these drymilling techniques is limited
to a few micrometers [69]. It was reported that when the sol-
ubility of a drug is very low, down-sizing it to the micrometer
range is insufficient to increase its dissolution rate and gastro-
intestinal absorption [70]. In the last decade, significant ad-
vancements and evolutions inmilling processes have enabled
the production of submicron-sized (<1 mm) or nanoparticles
[43]. This process may be termed as nanonization. Nano-
particles, sometimes termed as nanocrystals, are typically
200e500 nm in size [71], and are particularly suited for the
formulation of parenteral preparations. Nanoparticles
possess significant advantages over microparticles in
enhancing drug solubility. Most notably, the process of
nanonization increases not only the surface area and disso-
lution rate of the drug particles, but also the saturation solu-
bility of the drug. Ordinarily, the saturation solubility of a drug
is dependent on the temperature and solvent used for disso-
lution. When the size of drug particles falls below 1 mm,
dissolution pressure increases due to the strong curvature of
the particle surface. This leads to an increase in saturation
solubility in accordance to the Ostwald-Freundlich and Kelvin
equations. Hence, at the nanoparticulate level, the saturation
solubility of a drug becomes a function of particle size. The
increase in saturation solubility of the drug will increase the
concentration gradient for drug diffusion and promote drug
absorption. Additionally, it was reported that orally-delivered
nanoparticles displayed strong adhesive properties to the
mucosal surfaces of the gastro-intestinal tract, arising from
the increased van der Waals forces of attraction between the
nanoparticles and the gut wall. This would further contribute
to the increased absorption and bioavailability of drugs
administered as nanoparticles.
Drug nanoparticles are most commonly produced by wet
milling. As the name suggests, wet milling involves size
reduction of drug particles suspended in a liquidmedium that
may be aqueous or non-aqueous in nature. Wet milling is
particularly suited for potent drugs and drugs which possess
high residual moisture contents (>50% moisture) because dry
milling may be problematic for drugs of this nature. In wet
milling, a drug nanosuspension is produced as the end prod-
uct although for improved product stability (minimization of
Ostwald ripening and possible hydrolytic degradation of
drug), patient convenience and the drive towards green or
sustainable manufacturing processes, the nanosuspension
may subsequently be transformed into a solid dosage form
(e.g. tablets and capsules) by granulation, freeze drying and
spray drying [43] using suitable excipients or “matrix formers”
like mannitol or lactose. The dissolution rate of ezetimibe, a
lipid-lowering compound, was improved even after nano-
crystals of the drug were tableted without the inclusion of any
solubilizing agents like sodium lauryl sulfate [72]. Drug
nanoparticles may also be incorporated into polymer films[73] or layered on sugar beads [74]. It has been demonstrated in
many studies that these “solidification” processes retain the
mechanically-activated status and other desirable physical
attributes of the original, milled drug particles.
Two common “topedown” approaches for the production
of drug nanoparticles are media milling and high pressure
(piston-gap) homogenization. These two milling techniques
have been the focal point of research in the past decade due to
their ease of scale-up, robust processing, economic advan-
tages and acceptance by regulatory authorities. Since 2000,
the US Food andDrug Administration has approved numerous
products e.g. Rapamune® (sirolimus, Wyeth), TriCor® (fenofi-
brate, Abbott) and Megace® ES (megestrol acetate, Par Phar-
maceuticals) that have been produced by these techniques
[75]. Tables 1 and 2 summarize the current research on the
application of media milling and high pressure homogeniza-
tion in particle size reduction and solubility enhancement of
specific drugs.
6.2. Media milling
Media milling can be considered a modernized version of the
ball mill (Fig. 3). This technology, first developed by Liversidge
and co-workers [76,77], is a classical wet milling technique
wherein a sufficiently concentrated dispersion of drug parti-
cles in an aqueous or non-aqueous liquidmedium is subjected
to a traditional ball milling operation [77,78]. The liquid me-
dium prevents adhesion and subsequent compaction of the
milled drug particles on the wall of the vessel and/or the
surfaces of the milling balls, which is a common occurrence
when the drug is milled in its dry state. This improves the
yield of nanoparticles. The liquid may also serve additional
purposes such as lubrication and coating of the newly-formed
particle surfaces through various physicochemical in-
teractions like electrostatic and hydrophobic interactions
[79,80].
In media milling, mechanical attrition and impaction of
the suspended drug particles are brought about by grinding
balls, often termed as the milling media, constructed out of a
variety of material such as glass (yttrium-stabilized), zirco-
nium oxide, ceramics or highly cross-linked polystyrene
resins [78]. Pearl balls and beads are commonly used as well in
which case the techniques are termed pearl and bead milling,
respectively. Unlike ball milling where the whole vessel ro-
tates or oscillate/vibrates whilst in operation, the vessel re-
mains stationary in media milling. Movement of the balls is
initiated by a stirring or agitating device, often represented by
several discs mounted on a central shaft rotating at high ve-
locities, 20 000 rpm and above, within the vessel. For this
reason, media milling is sometimes known as “stirred-ball
milling”. Media milling is a continuous process wherein the
drug suspension is pumped through the milling chamber to
effect size reduction of the suspended material. Prior to their
exit from the milling chamber, the milled particles pass
through a screen that serves to separate the suspended, mil-
led particles from the milling media. Media milling has been
employed for particle size reduction of loviride [81], ezetimibe
[72], alpha-lipoic acid [82], ibuprofen [83], cinnarizine, nap-
roxen [74], ketoconazole, phenytoin [84] and candesartan cil-
exetil [85]. The majority of these cited studies involve the
Fig. 3 e Schematic representation of the media milling process. The milling chamber is charged with milling media. A crude
slurry consisting of drug, water and stabilizer is fed into the milling chamber and processed into a nanocrystalline
dispersion.
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able solid dosage form like dry powders and tablets. Less
conventionally, stable nanoparticles of naproxen, fenofibrate
and griseofulvin produced from wet-stirred media milling
have also been incorporated into hydroxypropylmethyl cel-
lulose polymer films [73]. The dissolution rates of the drugs
were improved by nanonization and based on x-ray diffrac-
tion and Raman spectroscopic analysis, the process of film
formation did not affect drug crystallinity. Another interesting
example is the incorporation of crystalline nanoparticles of
indomethacin, prepared by media milling, into coated
mannitol microparticles using an aerosol flow reactor
method. The nanostructured microparticles produced
exhibited rapid dissolution properties [86].
In recent years, there is a trend towards the use of milling
media of much smaller dimensions (<100 mm) to bring about
the nanonization of drugs. As it is difficult to separate milling
media of this size from the milled products using the con-
ventional screen separator without choking or plugging the
screen, centrifugal technology has been employed to effect
such separations. The Ultra Apex Mill (Kotobuki Industries) is
an example where centrifugal technology has been integrated
into the design of the mill to effectively separate the milling
media, which can range from 15 to 100 mm, from the milled
product. This mill has been successfully employed for the
production of nanoparticles of albendazole, danazol and
omeprazole as well as probucol [87] for the enhancement of
their dissolution and absorption properties.
A major drawback of media milling is the erosion of the
balls arising from the intensive mixing forces in the vessel.
Residues of the milling media produced from erosion may
result in product contamination [71,88,89], leading to chemi-
cal destabilization of the newly-formed particle surfaces and
possibly affecting critical product attributes such as particle
size and size distribution. Monitoring impurity levels in the
final milled product is thus warranted. Contamination prob-
lems may be mitigated by a prudent choice of the materialssuch as erosion-resistant polymers and ceramics, used in the
construct of the milling media as well as other key equipment
components (e.g. inner walls of milling chamber and stirring
device) in contact with the milled product. Optimization of
key process parameters like stirring speed and in particular,
milling time also contributes to reducing the likelihood of
erosion. This is becausemilling durations of up to several days
are not uncommon inmediamilling [77] and such longmilling
durations are likely to promote erosion of the milling media.
Commercially, media milling is exemplified by the Nano-
Crystal® technology from Elan Pharmaceutical Technologies.
To date, NanoCrystal®-based products have been approved by
worldwide regulatory agencies including the US, Canada, EU
and Japan.
6.3. High pressure homogenization
The production of nanosuspensions using high pressure or
piston-gap homogenization was first developed by Muller
et al. in 1994 [90]. It is a high energy process in which size
reduction of drug particles is achieved by repeatedly cycling,
to 200 plus cycles, with the aid of a piston, a drug suspension
through a very thin gap at high velocity, around 500 m/s, and
pressure, 1000e1500 bars (Fig. 4). The width of the gap, which
generally falls within the range of 5e20 mm, may be adjusted
according to the viscosity of the suspension and the applied
pressure. Pre-micronization of the starting materials using a
process like fluid-energy milling may be necessary prior to
homogenization. This is to minimize clogging of the homog-
enization gap and to reduce milling time. When the suspen-
sion is forced through the gap at a high flow rate, the static
pressure exerted on the liquid falls below the vapor pressure
of the liquid at the prevailing temperature (Bernoulli's equa-
tion). As a result, the liquid boils and gas bubbles are formed
which collapse when the liquid exits from the gap and normal
pressure is resumed. The powerful cavitation forces arising
from the formation and collapse of the gas bubbles, coupled
Fig. 4 e Schematic diagram of the high pressure
homogenization process. The microparticles are forced
through aminute gap in themicronizing zone. This creates
conditions of high turbulence and shear, combined with
compression, acceleration, pressure drop and impact,
leading to the formation of a nanosuspension.
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microparticles [91e93]. The extent of subdivision of the
nanoparticles depends on the pressure applied as well as the
number of passes or homogenization cycles the drug sus-
pension is subjected to during the process. The mechanical
properties (hardness) of the drug particles also affect the
milling outcome, with mechanically softer drug particles
achieving a lower (200e300 nm) nanometer size range even-
tually [7]. High pressure homogenization is a high energy
process. In the course of milling, the drug particles are
exposed to a power density of up to 1013 W/m3 which is
comparable to power densities observed in nuclear power
stations. The high energy impartedmechanically activates the
drug particles potentially leading to partial or complete
amorphization of the drug [94]. High pressure homogenizers
are available in different capacities, ranging from few tens of
milliliters for laboratory use to a few thousand liters for large
scale production. The process is robust and may easily be
adapted for aseptic production of parenteral drug nano-
suspensions. High pressure homogenization is employed for
the production of parenteral nutrition emulsions (e.g. Lip-
ofundin® and Intralipid®). High pressure homogenization also
enables continuous processing and unlike media milling,
contamination problem frommilling equipment is much less.
In the last decade or so, extensive research has been carried
out on the application of high pressure homogenization for
particle size reduction and solubility enhancement of drugs.
Table 2 summarizes the research reports in the area over the
recent years. Commercially, high pressure homogenization is
exemplified by the Dissocubes™ technology which has been
owned by SkyePharma PLC since 1999. Nanosuspensions
prepared using Dissocubes™ are water-based and are char-
acterized by well-defined particle sizes and narrow particle
size distributions, with few particles exceeding 5 mm in size
[95]. Many different drugs have been processed by theDissocubes™ technology resulting in bioavailability
enhancement.
In 1999, a variant of the high pressure homogenization
process, known as the Nanopure® (pure nanocrystals) tech-
nology, was introduced. This technology is owned and
developed by Pharmasol GmbH, Berlin. Homogenization in
this case is conducted in a non-aqueous dispersion medium,
polyethylene glycols, propylene glycol, water-alcoholic mix-
tures or suitable oils [96], rendering the process suitable for
comminuting drugs susceptible to hydrolysis. This technique
is also suitable for drugs that are thermolabile. This stems
from the option of conducting homogenization under milder
conditions such as reduced temperature [97] and in the event
where the nanosuspension has to be converted into a solid
form, less heat will be required for solvent removal (compared
to homogenization using water) thereby preserving drug sta-
bility. Supercritical CO2 has also been employed as a disper-
sion medium. In two recent studies, high pressure
homogenization of phenytoin [98] and ketoprofen [97]
dispersed in supercritical CO2 was carried out. The use of su-
percritical CO2 enhanced the efficiency of homogenization as
the liquid medium could be easily evaporated under ambient
conditions, allowing the milled product to be readily recov-
ered in the form of a dry powder.
High pressure homogenization has also been combined
with precipitation and this is marketed as the Nanoedge™
technology. In this technique, the drug is first dissolved in a
water-miscible alcoholic solvent (e.g. methanol, ethanol or
isopropanol), then added to water to cause it to precipitate.
The precipitated particles are subsequently homogenized.
The homogenization step is purported to reduce the size and
size distribution of the precipitated particles, thereby mini-
mizing the likelihood of crystal growth and improving the
stability of the nanosuspension during storage. Precipitation,
in tandem with high pressure homogenization, has been
successfully applied for the preparation of nitrendipine
nanocrystals to improve drug bioavailability. Chitosan, which
was used subsequently to modify the surfaces of the nano-
crystals, further enhanced drug bioavailability without
bringing about any measurable increase in the size of the
original nanocrystals [99].
6.4. Cryogenic milling
In principle, size reduction begins when the externally-
applied stress induces sufficient strain within the particles
and causes the formation of cracks. The cracks are then
propagated through lines of weaknesses in the material, with
new cracks being initiated and perpetuated along the way at
other discontinuities. A cascade effect occurs and material
fracture results. Themechanical property such as hardness or
elasticity of a drug is likely to affect the ease of crack initiation
and propagation during milling. Logically, harder materials
require greater energy input to effect particle size reduction as
they do not yield to the externally applied stress as readily as
softer materials. However, the brittleness or plasticity of the
material also plays a critical role in rendering the ease of
particle size reduction. It is easier to comminute hard and
brittle materials, such as chalk, than soft and viscoelastic
materials, such as rubber, waxes or natural gums. Instead of
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absorbing large amounts of energy through viscoelastic
deformation without crack initiation or propagation. At
ambient conditions, these materials resist fracture or may
even melt (for waxy materials) when exposed to the heat
generated during milling. Drug substances that exhibit such
characteristics are not likely to be amenable to the conven-
tional dry or wet milling methods aforementioned. However,
there had been few studies on the milling of soft and highly
plastic pharmaceutical materials [52].
Cryogenic milling or cryomilling in short, is a size reduc-
tion method specially catered to soft, elastic/plastic, non-
brittle and thermolabile materials. Cryomilling may be car-
ried out either by first freezing thematerials in liquid nitrogen
(100 to 150 C) prior to milling or by milling the materials
under cryogenic conditions, i.e., in the presence of liquid ni-
trogen (Fig. 5). Exposure to liquid nitrogen results in the
“embrittlement” of the material which facilitates crack prop-
agation, reducing the specific energy required for milling [100]
and potentially shortening the milling duration. Although
freeze drying performs a similar function and renders a ma-
terial brittle and porous, by virtue of the fact that it is a drying
process implies that it is more suitable for liquids or solid
materials containing higher residual moisture contents. Sal-
azar et al. [101] studied media milling and high pressure ho-
mogenization of glibenclamide that was first pre-treated by
freeze-drying. Freeze-drying rendered the drug brittle and
porous, facilitating the subsequent milling process. This
combination approach reduced milling time and improved
milling efficiency.
Cryomilling enables the production of both micron and
nano-sized particles but it has not beenwidely adopted in the
pharmaceutical industry for the milling of drugs. Sugimoto
et al. [102] studied the cryogenic co-milling of phenytoin and
polyvinylpyrrolidone as a means to improve the dissolution
rate of the drug. Phenytoin was dispersed in liquid nitrogen
and subjected to media milling using beads constructed out
of zirconium or dry ice. Spontaneous sublimation of the dry
ice beads together with liquid nitrogen at ambient condition
enabled the recovery of a high yield (85e90 %) of dry
phenytoin nanoparticles, since material loss arising from
adhesion to the surfaces of the milling media was of no
consequence. In another study, pluronic F-68, a soft andFig. 5 e A) Cryogenic mill, B) Schematic diagram showing a cro
atmosphere is supplied in the chamber.meltable material that may be used both as an excipient and
active ingredient in inhalable dry powder formulations [103],
was subjected to a micro-ball milling technique using stain-
less steel ball bearings as the grinding agent. Ball milling was
carried out in the presence of liquid nitrogen vapor. Apart
from chilling the chamber, the liquid nitrogen also prevented
plastic deformation of thematerial and improved the particle
fracture process [52].
Cryomilling is advantageous in that it minimizes the
degradation of thermolabile drug substances and loss of vol-
atile drug compounds. It also reduces the risk of explosion,
oxidation of formulation constituents and particle aggrega-
tion during the milling [104]. The latter stems from the low
surface tension and viscosity of liquid nitrogenwhich allows it
to penetrate into inter and intra-particulate void spaces and
micropores of the particles, forming a physical barrier which
prevents particle agglomeration [105]. Cryomilling decreases
the effect of temperature-induced changes during milling.
Jayasankar et al [106], in a study on co-crystal formation be-
tween carbamazepine and saccharin, reported that co-
grinding the drug and excipient under cryogenic conditions
was necessary to prevent the reaction from proceeding
through the melt phase which commonly occurs when co-
grinding is carried out at ambient conditions. Cryogenic co-
grinding also led to higher levels of amorphization than co-
grinding at room temperature. These results are echoed in
another study involving the ball milling of 3 different crys-
talline forms of piroxicam [107]. Differing extents of drug
amorphization was achieved by ball milling the drug under
different temperature conditions (ambient and cryogenic
conditions), with cryogenic ballmilling beingmore effective in
inducing drug amorphization. This is because milling at
cryogenic temperatures effectively ‘traps’ the milled material
in its amorphous state by removing the thermal energy
required for re-crystallization to occur [108]. In this regard,
cryogenicmilling is advantageous as it enables the production
of amorphous material without the deleterious effects of
solvents or heating [61]. Crowley and Zografi [109] studied the
cryogenic grinding of 5 crystal forms of indomethacin and
found that amorphization occurred for one of the solvates
(indomethacin methanolate) and all the three polymorphs (g,
a, and d) studied. Recently, g-indomethacin was subjected to
cryomilling and it was reported that the amorphousss-section of the cryogenic milling chamber. Cryogenic
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which was positively related to the duration of cryomilling
[38]. The same group of researchers had also evaluated the
physical stability of the cryomilled amorphous indomethacin
samples by measuring the time required for the drug to re-
crystallize on storage [110]. Cryogenic grinding was success-
fully used to convert crystalline glibenclamide to its amor-
phous form, averting possible chemical degradation during
the process. The crystalline-amorphous conversion was
shown to be connected with the amide-imidic acid tautom-
erism of glibenclamide [111]. Chieng and co-workers [112]
investigated the effect of cryomilling on 2 polymorphic
forms of ranitidine hydrochloride and evaluated the physical
stability of themilled amorphous drug under different storage
conditions.
High impact cryomilling thus enables the production of
completely amorphous drugs that may otherwise be difficult
to obtain by milling at room temperature. However, drug
amorphization may not always be advantageous from a sta-
bility point of view. In a recent study on the cryomilling of
furosemide, it was reported that the duration of cryomilling
and resultant drug amorphizationwere factors responsible for
the chemical decomposition of the drug [113]. Drug amorph-
ization may not occur in all cases. In a study by Niwa et al.
[114], the nanocrystals of phenytoin, ibuprofen and salbuta-
mol sulfate produced from an optimized cryomilling process
retained their crystalline character. This was explained by the
mild processing conditions that prevailed during cryomilling.
Feng et al. [115] reported that cryogenic milling of griseofulvin
led to a reduction in drug crystallinity due to the increase of
crystal defects, rather than the formation of amorphous drug.
A body of research on the use of cryomilling to process mo-
lecular materials, including model pharmaceutical com-
pounds, has been carried out by Willart and Descamps [108].
Table 3 summarizes the latest research findings on the use
of cryomilling for particle size reduction and solubility
enhancement of drugs.7. Process analytical technology (PAT) in
milling
In 2004, the Food and Drug Administration (FDA) initiated the
quality by design (QbD) concept, in which process analytics
are embedded to monitor, in real time, critical process and
product attributes rapidly and non-destructively. The aim of
the PAT initiative is to diminish the reliance on end product
testing to ascertain product quality, improve process under-
standing as well as develop intelligent sensing and responsive
manufacturing processes. It represents the agency's move to a
science-based approach to pharmaceutical manufacturing. In
line with this initiative, there is a need to implement process
analytical tools to achieve better understanding of the particle
phenomena during milling. As aforementioned, the size and
shape of milled particles can affect the dissolution properties,
resultant bioavailability and storage stability of the formu-
lated product. Hence, it is critical to monitor and track the
evolution of particle size and shape during milling. Laser
diffraction has become the method of choice for particle size
measurement during milling due to its versatility, rapid andreproducible particle sizing [116]. It uses light-scattering
measurements to calculate the volume-based particle size
distribution. In the last decade, alternative techniques to
characterize particle size distribution based on focused beam
reflectance measurement (FBRM), ultrasonic attenuation
spectroscopy (UAS), phase Doppler method (PDA), spatial
filtering technique (SFT) and shadow Doppler velocimetry
(SDV) have surfaced. FBRM uses a focused beam of laser light
that scans across a particle passing in front of the probe
window to measure a chord length distribution. UAS mea-
sures the volume-based particle size distribution from
extinction spectra using the fundamental equations of mass,
momentum and energy balance describing the interaction
between an ultrasonic wave and suspended particle. The PDA
is based upon the principles of light scattering interferometry
and measurements are made using the same optical probe as
for laser Doppler velocimetry (LDV). SFT uses the measuring
principles of the fiber optical spatial filtering velocimetry (SFV)
and the fiber optical spot scanning (FSS) in order to determine
simultaneously the size and the velocity of particles. SFV is a
method of the velocity determination of an object by
observing the object through a spatial filter in front of a
receiver. FSS is an addition to the SFV to observe the shadow
image of amoving particle through a single optical fiber with a
small diameter. SDV is based on the imaging of a conventional
LDV probe volume onto a linear photodiode array.
Particle size measurements can be made in-line or on-line.
In in-line particle sizing, a probe is directly inserted into the
process stream for measurements. However, the main process
streamoftenoperates athighparticleflowrates. It is therefore a
common method to measure in a side-stream that can be iso-
lated from the main process flow. Another option is the appli-
cation of a dilution step between the particle stream and the
measuringdevice. Inon-lineparticle sizing, a sample isdiverted
from the manufacturing process stream for measurement, to
circumvent the high particle flow rate in the main stream.
As particle shape along with size are directly related to the
product quality and performance, the use of a single param-
eter to describe the physical dimension of particles is often
insufficient, especially for non-spherical (rod or plate-like)
particles. Therefore, in-line or on-line particle sizing
together with shape measurement can play a crucial role in
controlling milling processes. However, little attention has
been given to real-time particle shape measurement due to
the lack of available technologies. Laser Doppler methods
have been employed to analyze particle shape, but only with
limited success [29,117,118]. Dynamic image analysis (DIA) is
still the most commonly used technique for particle shape
characterization. However, manual operation was required
for sample preparation, measurement and data analysis due
to low level of automation. Recent advancements in technol-
ogies of high speed cameras and computers have increased
the level of automation which enabled the measurement of
two dimensional images of dynamic particles [119]. DIA was
specifically suitable in sizing non-spherical particles [119,120].
However, the use of the DIA systems have beenmostly limited
to wet analysis, where particles are suspended in a liquid
medium to allow easy control of particle flow rate and
thus reduction of motion blur during image acquisition.
Recently, Sympatec Inc. (Clausthal-Zellerfeld, Germany)
Table 5 e Summary of different PAT approaches in milling.
Technique Mechanism Measurement parameters
Particle size analysis
Laser diffraction Light scattering Volume-based particle size distribution
FBRM (focused beam reflectance
measurement)
Focused beam laser light scan across a particle Particle chord length distribution
UAS (ultrasonic attenuation
spectroscopy)
Interaction between ultrasonic wave and suspended
particle
Volume-based particle size distribution
PDA (phase Doppler method) Light scattering interferometry Size, velocity and concentration of
spherical particles
SFT (spatial filtering technique) Combination of spatial filtering velocimetry (SFV)
and fiber optical spot scanning (FSS)
Particle chord length and velocity
SDV (shadow Doppler velocimetry) Doppler shift in a laser beam Particle size and velocity
Particle size and shape analysis
DIA (dynamic image analysis) Image analysis Particle size and shape analysis in
wet environment
DIA (QICPIC) Image analysis Particle size and shape analysis in
dry environment
DIA (Eyecon™) Image analysis using illumination technique 3D particle characterization
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capturing images of dry powder particles in a rapidly-moving
air stream. Another introduction of DIA system is the non-
invasive, real-time 3D particle characterizer capable of giv-
ing live particle size and shape information for coarser parti-
cles is the Eyecon™ (Innopharma Labs, Dublin, Ireland) which
uses a unique illumination technique to assist in detection of
particle boundaries. The different PAT approaches in milling
are summarized in Table 5.8. Conclusion
A feature of advancement in the pharmaceutical industry is
the increased use of materials, particularly drugs, in their
finest state of subdivision to enhance dissolution, solubility
and bioavailability. A myriad of milling techniques and
equipment are now available for particle size reduction of
drugs, with many capable of scaling up and adaptable to
consistent and continuous manufacturing. The application of
PAT tools in milling also improves process understanding as
well as facilitates the monitoring and control of the particle
size reduction process. This enables the production of fine
particulates with predictable and controllable physicochem-
ical characteristics. There are other aspects of milling that are
not within the scope of this review but nonetheless warrant
considerable attention. These include the possible cellular
toxicities of drug nanoparticles as well as the increased risks
of chemical degradation, polymorphism and loss of the ac-
tivities of drugs as a result of them being milled to a finely-
divided state. Despite recent progress and innovations in the
art ofmilling,much effort is still needed to improve the energy
efficiencies of milling operations particularly those designed
for ultrafine grinding. Even in the most efficient mills, as little
as 2% of the total energy consumption may be channeled to
effect particle size reduction, with the remainder being lost
via elastic/plastic deformation of particles, inter-particulate
and particle-machine friction, heat, sound and vibration
[121]. The use of milling as a means to engineer and produce
fine, surface-modified particles also represents an excitingarea of research wherein the function of milling extends
beyond size reduction and offers a more holistic and inte-
grated approach to particle design.r e f e r e n c e s
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